J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SRPT stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Anupam Rama’s rating is based on several strategic developments at Sarepta Therapeutics that indicate a positive outlook for the company. The recent updates from Sarepta have removed worst-case scenarios, such as the potential market withdrawal of Elevidys, which now carries a black box warning for certain patients. This development is seen as a positive step in stabilizing the company’s position and is expected to boost investor sentiment.
Anupam Rama also highlights Sarepta’s strategic restructuring efforts, which aim to significantly reduce operational expenses and save approximately $400 million annually. This cost management, combined with the company’s focus on promising siRNA programs and the long-term potential of its commercial franchises, supports the Buy rating. The anticipated revenue stability and strategic pipeline efforts further reinforce confidence in Sarepta’s future performance.
In another report released today, Mizuho Securities also maintained a Buy rating on the stock with a $40.00 price target.
SRPT’s price has also changed dramatically for the past six months – from $117.060 to $18.380, which is a -84.30% drop .